Skip to main content
PMC home page
Scientific Data logoLink to Scientific Data
. 2016 Feb 2;3:160004. doi: 10.1038/sdata.2016.4

DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing

Anneleen Decock 1,2, Maté Ongenaert 1, Wim Van Criekinge 3,4,5, Frank Speleman 1,2, Jo Vandesompele 1,2,6,a
PMCID: PMC4736656  PMID: 26836295

Abstract

Comprehensive genome-wide DNA methylation studies in neuroblastoma (NB), a childhood tumor that originates from precursor cells of the sympathetic nervous system, are scarce. Recently, we profiled the DNA methylome of 102 well-annotated primary NB tumors by methyl-CpG-binding domain (MBD) sequencing, in order to identify prognostic biomarker candidates. In this data descriptor, we give details on how this data set was generated and which bioinformatics analyses were applied during data processing. Through a series of technical validations, we illustrate that the data are of high quality and that the sequenced fragments represent methylated genomic regions. Furthermore, genes previously described to be methylated in NB are confirmed. As such, these MBD sequencing data are a valuable resource to further study the association of NB risk factors with the NB methylome, and offer the opportunity to integrate methylome data with other -omic data sets on the same tumor samples such as gene copy number and gene expression, also publically available.

Subject terms: DNA methylation, Paediatric cancer, Next-generation sequencing

Background & Summary

Neuroblastoma (NB), a neuro-ectodermal tumor that originates from precursor cells of the sympathetic nervous system, represents the most common extra-cranial solid tumor of early childhood and is considered a heterogeneous disease driven by genetic aberrations, as during the past decades mainly genetic factors have been described to influence the pathogenesis and disease course (including MYCN amplification, ALK amplification and mutation, hyperdiploidy, and gains and losses of specific chromosome arms (1p, 3p, 11q and 17q))1. Also, recent comprehensive whole-genome sequencing studies of primary NB tumors pinpointed chromothripsis and defects in neuritogenesis genes as important tumor-driving events in a subset of NB2, and indicated that MYCN, TERT and ATRX alterations define major subgroups of high-risk NB3,4. However, also epigenetic mechanisms, such as DNA methylation alterations, seem to contribute to the NB biology and clinical behaviour.

As reviewed in Decock et al.5, multiple DNA methylation alterations have been described in NB, but given the rare occurrence of the disease, the number of comprehensive genome-wide DNA methylation studies analyzing primary tumor samples is limited. Hence, most studies initially make use of NB cell lines and only validate the most obvious methylation alterations in primary NB tumors. For example, a frequently applied methodology to NB cell lines is assessment of gene expression reactivation upon 5’-aza-2’-deoxycytidine (DAC) treatment, a cytosine analogue that cannot be methylated, leading to progressive DNA demethylation upon cell division. However, major drawbacks of these studies are that their discovery phases fall short in covering the NB heterogeneity, as NB cell lines are considered models for aggressive high-risk tumors, and that DNA methylation detection is indirectly assessed, as the influence of the demethylating effect is measured at the transcriptional level6–8. To accommodate this, the Illumina 27 and 450 K methylation arrays, directly interrogating the status of approximately 27,000 and 485,000 methylation sites, respectively, recently were applied to primary NB tumors6,9–12. Yet, also this technology has important limitations: the design of the arrays is heavily biased to interrogation of CpG sites previously described in literature and covers less than 2% of all CpG sites in the human genome13.

Therefore, we generated a data set comprising of 102 primary NB tumors in which DNA methylation is assessed by massively parallel sequencing of methylation enriched DNA fragments. The applied method is based on the use of MeCP2, a member of the methyl-CpG-binding domain (MBD) protein family which specifically binds to methylated cytosines and enables precipitation of methylated DNA fragments. This data set is unique in the NB research field, as it is the first sample cohort in which the full tumor heterogeneity is being assessed by genome-wide methylation analysis using next-generation sequencing (NGS); it was originally collected for the identification of prognostic biomarker candidates. Selected candidates were validated in independent cohorts using methylation-specific PCR and we showed that MBD sequencing allowed selection of valuable markers which would not have been identified using the Illumina methylation arrays14.

Here, we provide a detailed description of the methodological approach and bioinformatics analyses, as well as easy access to the (analyzed) MBD sequencing data and analysis tools, allowing other researchers (inexperienced with MBD sequencing) to reuse it. Importantly, the analyzed samples are well annotated; besides overall and event-free survival data, also following NB characteristics are available: age of the patient at diagnosis, tumor stage according to the International Neuroblastoma Staging System (INSS)15 and MYCN amplification status. As such, these data offer the opportunity to further explore the association of these risk factors with the NB methylome. Furthermore, integration of methylome data with other -omic data sets should be examined in order to fully map the NB biology on a genome-wide level. The present MBD sequencing data greatly facilitate these integration analyses, considering that for part of the profiled samples matching expression and array comparative genomic hybridization (aCGH) data are available16–18 (see Methods for details).

In summary, this data descriptor outlines details on the generation and analysis of MBD sequencing data of 102 primary NB tumors (Fig. 1). As NB is a rare disease and comprehensive DNA methylation studies scarce, these MBD sequencing data are very valuable and permit further unravelling the role of DNA methylation in the NB biology.

Figure 1. The MBD sequencing data of 102 primary neuroblastoma tumors are processed using different analysis tools.

Figure 1

Open in a new tab

Depicted are the available MBD sequencing data sets and downstream data processing and technical validation steps. These steps are represented as arrows and circles, respectively. For each step, the applied tool or analysis is indicated. For the technical validation steps, also the corresponding data descriptor figures and tables are indicated. DMA, differential methylation analysis; IGV, Integrative Genomics Viewer; PE, paired-end; RPKM, reads per kilobase CpG island per million.

Methods

DNA sample collection

Two independent cohorts of 42 and 60 primary tumor DNA samples, respectively annotated as MBD cohort I and II, were sequenced. Samples of fresh frozen tumors were collected at the Ghent University Hospital (n=49; Ghent, Belgium), the Hospital Clínico Universitario (n=42; Valencia, Spain), the University Children’s Hospital Essen (n=8; Essen, Germany) and the Our Lady’s Children’s Hospital Dublin (n=3; Dublin, Ireland), according to previously published criteria7,14, and stage 4S tumors were also included. Detailed clinical characteristics of the patients are given in Table 1 (available online only). For samples 809 and 912, DNA was extracted from different parts of the same primary tumor. Informed consent was obtained from each patient’s guardian and the study was approved by the ethical committee of the Ghent University Hospital (approval number B67020109912). Matching expression data16,17 of 38 tumors are available through the NCBI Gene Expression Omnibus (GEO) database (GSE21713 and GSE32664; sample IDs in Table 1 (available online only)). Matching aCGH data18 of 38 tumors are available through ViVar19 (https://www.cmgg.be/vivar/; login: review, password: review, project: Kumps et al. 2013; sample IDs in Table 1 (available online only)).

Table 1. In total, 102 annotated primary neuroblastoma DNA samples were profiled by MBD sequencing.

Source Name Characteristics[organism] Characteristics[organism part] Method Sample Name Factor Value[cohort] Factor Value[age at diagnosis (months)] Factor Value[INSS stage] Factor Value[MYCN amplification status] Factor Value[overall survival time (days)] Factor Value[event-free survival time (days)] Factor Value[overall survival status] Factor Value[event-free survival status] Factor Value[expression data_GEO ID] Factor Value[aCGH data_ViVar ID]
Each sample is characterized by a unique Sample Name and is assigned to a specific cohort (MBD cohort I or MBD cohort II). Clinical characteristics given are the age at diagnosis in months, International Neuroblastoma Staging System (INSS) stage, MYCN amplification status (non-amplified or amplified), and overall survival (OS) and event-free survival (EFS) status and time in days after diagnosis. The OS status indicates whether the patient was alive at the last known follow-up or died of disease. Similarly, the EFS status indicates events such as relapse, progression or death. For each sample, the GEO accession IDs are provided. For samples for which expression and/or aCGH data are available, also the corresponding accession IDs to these data are indicated. NAs represent missing data.                            
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 811 MBD cohort I 66.70684932 4 non-amplified 944 587 died of disease event GSE21713—GSM541724 id 4883
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1429 MBD cohort I 64.63561644 4 non-amplified 1188 867 died of disease event GSE21713—GSM541703 id 4758
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1467 MBD cohort I 0 4 amplified 1 1 died of disease event GSE21713—GSM541689 id 4817
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1473 MBD cohort I 7.528767123 4 amplified 239 116 died of disease event GSE21713—GSM541691 id 4882
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1477 MBD cohort I 78.70684932 4 amplified 1246 898 died of disease event NA id 4600
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1517 MBD cohort I 34.88219178 4 non-amplified 547 433 died of disease event GSE21714—GSM541705 id 11565
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1520 MBD cohort I 39.74794521 4 amplified 1279 552 died of disease event GSE21713—GSM541694 id 11771
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1522 MBD cohort I 22.61917808 3 amplified 728 594 died of disease event GSE21713—GSM541696 id 5098
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1527 MBD cohort I 107.9342466 4 amplified 319 NA died of disease event GSE21713—GSM541698 id 4762
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1648 MBD cohort I 53.16164384 4 non-amplified 1221 341 died of disease event GSE21713—GSM541701 id 4603
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection E061 MBD cohort I 30.70684932 4 non-amplified 1445 497 died of disease event GSE32664—GSM810696 id 5143
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection E069 MBD cohort I 59.44109589 4 non-amplified 2836 2016 died of disease event GSE32664—GSM810694 id 5095
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection E282 MBD cohort I 16.99726027 4 amplified 711 433 died of disease event GSE32664—GSM810699 id 5142
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection E290 MBD cohort I 6.443835616 4 amplified 539 351 died of disease event GSE32664—GSM810682 id 5085
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 526 MBD cohort I 26.43287671 4 amplified 2009 2009 alive no event GSE21713—GSM541725 id 4866
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1017 MBD cohort I 22.32328767 3 amplified 1758 1758 alive no event GSE21713—GSM541728 id 4910
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1431 MBD cohort I 23.04657534 4 amplified 953 953 alive no event GSE21713—GSM541704 id 4550
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1521 MBD cohort I 38.03835616 4 amplified 2163 2163 alive no event GSE21713—GSM541695 id 4602
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1524 MBD cohort I 23.30958904 3 amplified 2387 2387 alive no event GSE21713—GSM541697 id 4766
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1616 MBD cohort I 18.34520548 4 amplified 2137 2137 alive no event GSE21713—GSM541690 NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 2857 MBD cohort I 28.83287671 3 amplified 1295 1295 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 2863 MBD cohort I 10.81643836 4 amplified 1237 1237 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 2868 MBD cohort I 157.1835616 4 non-amplified 1159 1159 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection E579 MBD cohort I 13.15068493 4 non-amplified 3534 3534 alive no event GSE32664—GSM810692 id 4913
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection E598 MBD cohort I 48.85479452 4 non-amplified 3219 3219 alive no event GSE32664—GSM810689 id 5137
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection E685 MBD cohort I 14.16986301 4 non-amplified 3011 3011 alive no event GSE32664—GSM810685 id 5043
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection E700 MBD cohort I 20.35068493 4 non-amplified 1536 1536 alive no event GSE32664—GSM810680 id 5041
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 278 MBD cohort I 14.53150685 1 non-amplified 3404 3404 alive no event GSE21713—GSM541713 id 4884
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 397 MBD cohort I 18.47671233 2 non-amplified 3555 3555 alive no event GSE21713—GSM541720 id 10138
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 410 MBD cohort I 1.676712329 1 non-amplified 2910 2910 alive no event GSE21713—GSM541714 id 4878
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 529 MBD cohort I 1.249315068 3 non-amplified 2264 2264 alive no event GSE21713—GSM541707 id 4863
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 530 MBD cohort I 1.545205479 1 non-amplified 2216 2216 alive no event GSE21713—GSM541717 id 4785
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 566 MBD cohort I 0.098630137 2 non-amplified 1615 1615 alive no event GSE21713—GSM541718 id 4826
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 711 MBD cohort I 16.99726027 2 non-amplified 1885 1885 alive no event GSE21713—GSM541710 id 11562
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 744 MBD cohort I 16.0109589 2 non-amplified 1850 1850 alive no event GSE21713—GSM541716 id 4870
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 747 MBD cohort I 7.989041096 1 non-amplified 2302 2302 alive no event GSE21713—GSM541712 id 11563
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 809 MBD cohort I 0.164383562 1 non-amplified 2904 2904 alive no event GSE21713—GSM541723 id 4868
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 914 MBD cohort I 1.249315068 1 non-amplified 2425 2425 alive no event GSE21713—GSM541711 id 11564
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 916 MBD cohort I 9.994520548 1 non-amplified 3830 3830 alive no event GSE21713—GSM541726 id 5372
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 926 MBD cohort I 0.920547945 1 non-amplified 1861 1861 alive no event GSE21713—GSM541715 id 4921
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1650 MBD cohort I 0.854794521 2 non-amplified 1264 187 alive event GSE21713—GSM541702 id 4813
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1699 MBD cohort I 7.463013699 3 non-amplified 2882 999 alive event GSE21713—GSM541706 id 10132
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 41 MBD cohort II 49.90684932 4 non-amplified 569 NA died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 610 MBD cohort II 34.02739726 4 amplified 850 NA died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 928 MBD cohort II 11.7369863 4 amplified 412 NA died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1430 MBD cohort II 35.4739726 4 non-amplified 520 391 died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1507 MBD cohort II 14.33424658 4 amplified 285 NA died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1713 MBD cohort II 40.99726027 4 non-amplified 581 449 died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1780 MBD cohort II 30.90410959 3 amplified 569 NA died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1782 MBD cohort II 41.49041096 4 amplified 707 441 died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1783 MBD cohort II 13.6109589 4 amplified 316 288 died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1784 MBD cohort II 76.5369863 4 amplified 1819 972 died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1786 MBD cohort II 15.02465753 4 amplified 950 607 died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1790 MBD cohort II 101.2931507 4 non-amplified 989 306 died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1791 MBD cohort II 51.32054795 4 non-amplified 377 357 died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1795 MBD cohort II 134.0383562 4 non-amplified 671 214 died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1796 MBD cohort II 24.2630137 4 non-amplified 414 NA died of disease event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 11 MBD cohort II 15.22191781 4 non-amplified 4396 4396 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1030 MBD cohort II 54.64109589 4 non-amplified 2653 2653 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1381 MBD cohort II 21.46849315 4 non-amplified 1981 1981 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1382 MBD cohort II 70.09315068 4 non-amplified 1891 1891 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1384 MBD cohort II 16.37260274 3 amplified 1620 1620 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1501 MBD cohort II 131.3753425 4 non-amplified 1558 1558 alive event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1515 MBD cohort II 15.97808219 4 non-amplified 1687 1687 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1647 MBD cohort II 10.06027397 2 amplified 2136 2136 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1649 MBD cohort II 8.745205479 4 amplified 2174 2174 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1789 MBD cohort II 25.18356164 3 amplified 5616 5616 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1793 MBD cohort II 32.54794521 3 amplified 2328 2328 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1794 MBD cohort II 33.23835616 3 amplified 5096 5096 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1800 MBD cohort II 71.07945205 4 amplified 1862 1862 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1803 MBD cohort II 19.36438356 4 amplified 2410 2410 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1863 MBD cohort II 168.6246575 4 non-amplified 1053 560 alive event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 820 MBD cohort II 10.88219178 2 non-amplified 4794 4794 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 822 MBD cohort II 12.82191781 1 non-amplified 1153 1153 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 823 MBD cohort II 4.24109589 1 non-amplified 1090 1090 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 912 MBD cohort II 0.164383562 1 non-amplified 2904 2904 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1028 MBD cohort II 3.484931507 2 non-amplified 2932 2932 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1038 MBD cohort II 11.4739726 2 non-amplified 1071 1071 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1039 MBD cohort II 7.956164384 3 non-amplified 1394 1394 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1469 MBD cohort II 1.446575342 1 non-amplified 3275 3275 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1476 MBD cohort II 22.22465753 2 non-amplified 2075 2075 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1483 MBD cohort II 0.690410959 1 non-amplified 2554 2554 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1484 MBD cohort II 1.347945205 1 non-amplified 2566 2566 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1486 MBD cohort II 11.50684932 1 non-amplified 2328 2328 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1488 MBD cohort II 2.432876712 2 non-amplified 1827 1827 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1509 MBD cohort II 1.019178082 3 non-amplified 2597 2597 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1646 MBD cohort II 4.109589041 2 non-amplified 2096 2096 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1530 MBD cohort II 0.098630137 4S non-amplified 2039 2039 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1494 MBD cohort II 1.084931507 4S non-amplified 1590 1590 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1615 MBD cohort II 0.295890411 4S non-amplified 1562 1562 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1613 MBD cohort II 0.460273973 4S non-amplified 1503 1503 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1191 MBD cohort II 1.709589041 4S non-amplified 2105 2105 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1750 MBD cohort II 0.723287671 4S non-amplified 1322 1322 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 277 MBD cohort II 2.367123288 4S non-amplified 2099 101 alive event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1392 MBD cohort II 3.484931507 4S non-amplified 3190 3190 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 821 MBD cohort II 2.038356164 4S non-amplified 2652 2652 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 750 MBD cohort II 8.482191781 4S non-amplified 1567 1567 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1383 MBD cohort II 0.493150685 4S non-amplified 2670 2670 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1013 MBD cohort II 2.432876712 4S non-amplified 2252 2252 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 511 MBD cohort II 3.682191781 4S non-amplified 3837 3837 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 520 MBD cohort II 0.328767123 4S non-amplified 3703 3703 alive no event NA NA
Neuroblastoma patient Homo sapiens Primary tumor DNA sample collection 1537 MBD cohort II 0.55890411 4S amplified 2178 2178 alive no event NA NA
Open in a new tab

Methyl-CpG-binding domain (MBD) sequencing

DNA fragmentation

For each sample, between 400 to 1000 ng DNA was sheared to obtain DNA fragments with an average length of 200 bp. The DNA was loaded in 120 μl TE buffer (1:5), transferred to a Snap Cap microTUBE (Covaris) and exposed to Covaris S2 Adaptive Focused Acoustics. Fragment distribution and concentration was determined on a High Sensitivity DNA chip (Agilent Technologies).

Methylated DNA capturing

Subsequently, capturing of methylated DNA fragments was done according to the MethylCap kit protocol of Diagenode using 200–500 ng DNA. Elution of the captured fraction was performed in 150 μl High Elution Buffer and DNA was purified using the MinElute PCR purification kit (Qiagen). For MBD cohort II, also input samples (10%) were prepared.

Library preparation

As MBD cohort I and II were profiled in a different time frame and NGS methodologies evolve at rapid pace, a different library preparation protocol and sequencing technology was applied to each of them. For MBD cohort I, DNA library preparation was performed using the NEBNext DNA Library Prep Master Mix Set for Illumina (New England Biolabs) in combination with the Multiplexing Sample Preparation Oligonucleotide Kit (Illumina) for paired-end adapter ligation. Size selection of the library is done on a 2% agarose gel (Bio-Rad). Fragments between 250 and 350 bp were excised and purified using a Qiagen Gel Extraction Kit. For MBD cohort II, library preparation was automated on an Apollo 324 Next Generation Sequencing Library Preparation System (IntegenX), making use of the PrepX ILM DNA Library Kit (IntegenX). For paired-end adapter ligation the Multiplexing Sample Preparation Oligonucleotide Kit was used. Size selection was done with 1X AMPure XP beads (Agencourt) and PEG-Bead Solution.

Library amplification

PCR library amplification with appropriate Index Primers for each sample was performed using the Multiplexing Sample Preparation Oligonucleotide Kit and following PCR conditions: 30 s at 98 °C, 21 amplification cycles (10 s at 98 °C, 30 s at 65 °C and 30 s at 72 °C), 5 min at 72 °C, and held at 4 °C. PCR product purification was done using the High Pure PCR Purification Kit (Roche). QC was performed on a DNA 1000 chip (Agilent) and concentration was determined by qPCR according to the qPCR Quantification Protocol Guide of Illumina. Samples were pooled and profiled on an Illumina GAIIx (PE 2×45 bp) for MBD cohort I and on an Illumina HiSeq2000 (PE 2×51 bp) for MBD cohort II.

Data processing and analysis

Sequencing data

All crucial steps in the processing and analysis of the MBD sequencing data are summarized in Fig. 1. Raw sequencing data were demultiplexed and converted to FASTQ files (with sequencing reads and quality scores). Quality control on the raw data was performed by FASTQC (version 0.9.2; http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).

Read mapping

Next, the sequencing reads were mapped/aligned to the human reference genome (hg19), using the Bowtie2 (ref. 20) mapper (version 2.0.0 beta7) and FASTQ files as input. For each sample, two paired FASTQ files are available (as we performed paired-end sequencing), in which the data lines correspond to each other. To improve the mapping quality, reads were only taken into account if the sequences in both files could be mapped to the reference genome (maximum 500 bp between both paired ends). Also sequencing quality scores were used in the mapping process. The BAM format was used as output file type. PCR duplicates were marked with Picard (version 1.79; http://broadinstitute.github.io/picard/) and the BAM files were sorted and indexed using SAMtools21 (version 0.1.18) and index commands. These files have been deposited as raw data files in the NCBI Gene Expression Omnibus (GEO) database (Data Citation 1 for MBD cohort I; Data Citation 2 and Data Citation 3 for MBD cohort II). FASTQ records can be extracted from the sequence alignments in the BAM files using the BEDTools bamtofastq conversion utility22. Starting from the SRA files, the NCBI SRA Toolkit (fastq-dump) can be used to generate the FASTQ files. Mapping quality was evaluated using SAMStat23 (version 1.08) and BamUtil (version 1.0.2; http://genome.sph.umich.edu/wiki/BamUtil). Technical validation of MBD enrichment is performed by fragment CpG plot analysis24 and by plotting the densities of the median numbers of mapped reads per kilobase per million (RPKM25) in all CpG islands (n=28,691) across the different subcohorts.

Peak calling

The process of converting mapped sequencing reads to coverage vectors and the detection of enriched regions (peaks) is referred to as peak detection or peak calling. Here, peak calling was done using the MACS26 software tool (version 1.4.0 beta) and BAM files as input. BED files were generated (Data Citation 1 for MBD cohort I; Data Citation 2 and Data Citation 3 for MBD cohort II), indicating the location and score (linked to the P-value) of the identified peaks.

Visualization

MACS is also used to output WIG files (Data Citation 1 for MBD cohort I; Data Citation 2 and Data Citation 3 for MBD cohort II), which are transformed to a binary format (TDF file; Data Citation 1 for MBD cohort I; Data Citation 2 and Data Citation 3 for MBD cohort II) by igvtools (https://www.broadinstitute.org/igv/igvtools) for visualization in the Integrative Genomics Viewer (IGV)27. An example IGV XML-session file for MBD cohort II and instructions on how to make use of this file are included in the GitHub repository (see Code availability).

Differential methylation analyses

Differential methylation analyses between sample groups are described in detail in Decock et al.14. Briefly, for each subcohort, two count data sets were constructed, in which for each sample the numbers of mapped reads in the promoter region of the different Ensembl Transcripts or 5 kb genomic windows are indicated. Here, we provide access to these count data sets (Supplementary Tables 3,4,5,6,7,8), which can directly be used for differential methylation analyses in DESeq14,28.

Code availability

All tools and code that are necessary to generate the described file types are provided in a Docker container (Docker Hub; https://hub.docker.com/r/mateongenaert/mbdtoolbox/). More advanced analysis scripts can be found in the GitHub repository (https://github.com/mateongenaert/MBDToolBox).

Data Records

An overview of the sample annotation and data outputs is given in Table 1 (available online only). The outputs of each step in the data processing (read mapping: BAM files, peak calling: BED files, and visualization: WIG and TDF files) have been deposited in the GEO database. For MBD cohort I, the accession number is GSE69224 (Data Citation 1), for MBD cohort II, GSE69243 (Data Citation 2) and GSE69268 (Data Citation 3). In GEO, these data sets were submitted as SubSeries of the SuperSeries GSE69279 (Data Citation 4). We also provide a Docker container, made available through Docker Hub, that embeds all necessary tools to generate the data files and illustrates the analysis pipeline. More advanced analysis scripts are given in the GitHub repository (see Code availability).

Technical Validation

Validation of raw and mapped sequencing data

The total read number and percentage of duplicate and properly paired reads in each sample are given in Supplementary Table 1, and a summary of these sequencing statistics across the different sample cohorts can be found in Table 2.

Table 2. Using BamUtil, basic sequencing statistics of MBD cohort I and II are computed.

Statistic MBD cohort I—enriched samples
     MBD cohort II—enriched samples
 MBD cohort II—input samples
range mean median range mean median range mean median
Total read number: the total number of reads in the two paired FASTQ files of a sample; duplicate reads as a percentage of the total read number; properly paired reads as a percentage of the total read number.                  
total read number (e6) 4.65–18.20 13.38 14.17 29.74–66.59 45.09 44.41 20.86–59.51 36.00 33.19
duplicate reads (%) 0.70–72.00 6.46 3.39 2.55–79.69 31.04 19.89 2.24–10.47 4.17 3.68
properly paired reads (%) 48.29–94.51 85.64 89.29 86.86–97.57 95.33 95.72 94.78–97.55 96.50 96.59
Open in a new tab

To ensure raw data quality, FASTQC analyses were performed to determine the per base sequence quality which reflects the probability that a base has been called incorrectly29. Quality scores between 41 and 28, 28 and 20, and below 20 are considered base calls of very good quality, calls of reasonable quality and calls of poor quality, respectively. In order to obtain a general overview of the range of quality values across all bases at each position, the median quality score for each position in each FASTQ file was determined. Fig. 2 shows the distribution of these median per base quality scores across the different sample cohorts. In general, the quality scores of both MBD cohort I and II are of reasonable to very good quality. Given the different sequencing technologies that were used for MBD cohort I (Illumina GAIIx) and II (Illumina HiSeq2000), it is expected that the read quality of MBD cohort II is higher than that of MBD cohort I. The steadily increase and subsequent decrease in quality along the read is also expected for Illumina-based experiments29,30.

Figure 2. The per base sequence quality scores indicate that the raw sequencing data are of good quality.

Figure 2

Open in a new tab

Shown are the distributions of the median per base quality score (determined by FASTQC) of the enriched samples of MBD cohort I (a), and of the enriched (b) and input (c) samples of MBD cohort II. In the boxplots, the lower and upper hinge of the boxes represents the 25th and 75th percentile, respectively. The whiskers extend to the lowest and highest value that is within 1.5 times the interquartile range. Data beyond the end of the whiskers are outliers and plotted as dots.

Mapping quality is ensured by analyzing the mapping quality scores of the alignments in each sample (Supplementary Table 2). In Fig. 3, the distributions of the percentages of mapped reads across the different mapping quality ranges are shown. For all subcohorts, the reads are clearly mapped with high accuracy, as almost for every sample, more than half of the mapped reads has a MAPQ≥30 (ref. 23).

Figure 3. The mapping quality scores illustrate high mapping accuracy.

Figure 3

Open in a new tab

Shown are the distributions of the percentages of mapped reads across the different mapping quality ranges, as determined by SAMStat ((a) enriched samples of MBD cohort I, (b) enriched samples of MBD cohort II and (c) input samples of MBD cohort II). In the boxplots, the lower and upper hinge of the boxes represents the 25th and 75th percentile, respectively. The whiskers extend to the lowest and highest value that is within 1.5 times the interquartile range. Data beyond the end of the whiskers are outliers and plotted as dots.

Validation of MBD-based enrichment

Over the past years several companies developed commercial kits for MBD-based capturing of methylated fragments. Although all of them claim to be of high quality, differences in performance exist. Careful kit selection is thus of utmost importance24. Here, sheared tumor DNA was enriched towards methylated fragments using the MethylCap kit of Diagenode, that makes use of the methylCap protein, consisting of the MBD of human MeCP2 fused with gluthatione-S-transferase (GST) containing an N-terminal His6-tag. A previous evaluation assessed the quality of this kit for combination with NGS by comparison with four other commercially available kits24. This study also compared the MBD sequencing data with reduced representation bisulfite sequencing (RRBS) and Illumina 27 K methylation array data of the same samples. Together, these analyses showed that the MethylCap kit outperforms the others, due to a consistent combination of high yield, sensitivity and specificity24. In order to demonstrate that the samples of MBD cohort I and II were enriched for methylated DNA fragments after MBD-based capturing, we made use of the fragment CpG plot24. As this plot depicts the CpG content of the mapped fragments and the MethylCap kit theoretically only captures methylated cytosines in a CpG dinucleotide context, the fragment CpG plot can be used to evaluate the MBD-based enrichment. An overview of the CpG content of the mapped fragments per sample cohort is depicted in Fig. 4. This fragment CpG plot clearly illustrates that the MBD-enriched samples of MBD cohort I and II have a high fraction of CpG dense fragments, while the input (non-MBD-enriched) samples of MBD cohort II are not enriched in CpG content. Additionally, using the number of mapped reads per kilobase CpG island per million (RPKM) values25, the methylation level of each CpG island across the different subcohorts was determined. The density plot in Fig. 5 indicates that the MBD-enriched samples have a higher fraction of CpG islands with an RPKM>1 compared to the input samples of MBD cohort II. Based on these analyses, it can be concluded that the MBD-based capture successfully led to the enrichment of methylated DNA fragments.

Figure 4. Fragment CpG plots demonstrate that the MBD-enriched samples have a high fraction of CpG dense sequencing fragments.

Figure 4

Open in a new tab

Shown are the fractions of mapped MBD sequencing fragments with different CpG counts. Per cohort, 100,000 randomly selected fragments of each sample were used to construct the plots.

Figure 5. CpG island RPKM values confirm enrichment towards methylated DNA fragments upon MBD capture.

Figure 5

Open in a new tab

Shown are the densities of the median RPKM values per subcohort. RPKM: reads per kilobase CpG island per million.

Validation of methylated genes in neuroblastoma

Finally, TDF and BED files, containing sequence coverage and peak locations respectively, were loaded into IGV to visually inspect genes previously described to be methylated in NB. As an example, the MBD sequencing data of the PCDHB gene cluster is shown in Fig. 6. This gene cluster is frequently methylated in NB5,31, which is confirmed by the MBD sequencing data of both MBD cohort I and II. Additionally, 78 regions identified in the MBD sequencing data as being methylated, were validated in two independent patient cohorts using methylation-specific PCR (MSP)14. These data confirm the validity of MBD sequencing in identifying methylated regions in NB.

Figure 6. Visualization of the MBD sequencing data in IGV confirms methylation of the PCDHB gene cluster.

Figure 6

Open in a new tab

In (a) the data of MBD cohort I is shown, in (b) the data of MBD cohort II. The upper panels show the genes in the cluster, the location of CpG islands and the GC percentage. In the lower panels, sequence coverage of 6 high-risk patient samples is shown (peak pattern), as well as the location of identified peaks (horizontal bars).

Usage Notes

The MBD sequencing data can be downloaded from the GEO database via accession numbers GSE69224 (for MBD cohort I; Data Citation 1), GSE69243 and GSE69268 (for MBD cohort II; Data Citation 2 and Data Citation 3; SuperSeries GSE69279 (Data Citation 4)). The unique GEO sample accession IDs and clinical annotation can be found in Table 1 (available online only). This table also contains the accession IDs of the matching expression and aCGH data, which allows easy data access and facilitates integration analyses.

All output files from the different steps in the MBD sequencing data processing are provided through GEO. Analysis tools and scripts have been embedded in a Docker container, to deliver an environment that runs on any supported host platform (Windows, MAC, Linux). This Docker container, and all instructions on how it is made and how analyses can be run on the data, are made available through Docker Hub and GitHub (see Code availability). This allows researchers to try out the analysis pipeline that was used to generate the publically available data, without the need of additional infrastructure or software versions. The Docker container guarantees that the provided commands work and allows researchers to start exploring the data at the level they are experienced with.

Alternative processing tools can be tested for read mapping (e.g., BWA32) or identification of enriched regions (e.g., PeakRanger33 or BALM34), or absolute methylation scores can be calculated (MEDIPS35; see Code availability). Researchers inexperienced with MBD sequencing can easily visualize their genes of interest by downloading the BED and TDF files (see Code availability). Downstream differential methylation analyses can be done with DESeq28 (as described in Decock et al.14) using count data sets provided in Supplementary Tables 3,4,5,6,7,8, or other software can be used, such as DiffBind36 and edgeR37. Differences in absolute methylation scores can be used for RankProd38 analyses.

Additional information

Table 1 is only available in the online version of this paper.

How to cite this article: Decock, A. et al. DNA methylation profiling of primary neuroblastoma tumors using methyl-CpG-binding domain sequencing. Sci. Data 3:160004 doi: 10.1038/sdata.2016.4 (2016).

Supplementary Material

Supplementary Table 1

Using BamUtil, basic sequencing statistics of each sample of MBD cohort I and II are computed. Given are the total read numbers, and the number and percentage of properly paired and duplicate reads of each sample of MBD cohort I (a) and II (enriched samples in (b); input samples in (c)).

sdata20164-s2.xls (31.5KB, xls)
Supplementary Table 2

Using SAMStat, the mapping quality scores of each sample of MBD cohort I and II are analyzed. Given are the numbers and percentages of mapped reads across the different mapping quality ranges, as determined by SAMStat ((a) enriched samples of MBD cohort I, (b) enriched samples of MBD cohort II and (c) input samples of MBD cohort II).

sdata20164-s3.xls (49.5KB, xls)
Supplementary Table 3

Promoter count data for the MBD-enriched samples of MBD cohort I. For each MBD-enriched sample of MBD cohort I, the number of mapped reads in each Ensembl Transcript promoter region (-1500 bp to +500 bp around TSS) is given.

sdata20164-s4.txt (22.1MB, txt)
Supplementary Table 4

Promoter count data for the MBD-enriched samples of MBD cohort II. For each MBD-enriched sample of MBD cohort II, the number of mapped reads in each Ensembl Transcript promoter region (-1500 bp to +500 bp around TSS) is given.

sdata20164-s5.txt (35.1MB, txt)
Supplementary Table 5

Promoter count data for the input samples of MBD cohort II. For each input sample of MBD cohort II, the number of mapped reads in each Ensembl Transcript promoter region (-1500 bp to +500 bp around TSS) is given.

sdata20164-s6.txt (37.5MB, txt)
Supplementary Table 6

Window count data for the MBD-enriched samples of MBD cohort I. For each MBD-enriched sample of MBD cohort I, the number of mapped reads in each 5 kb genomic window (2.5 kb overlapping moving windows) is given.

sdata20164-s7.txt (172.1MB, txt)
Supplementary Table 7

Window count data for the MBD-enriched samples of MBD cohort II. For each MBD-enriched sample of MBD cohort II, the number of mapped reads in each 5 kb genomic window (2.5 kb overlapping moving windows) is given.

sdata20164-s8.txt (239.7MB, txt)
Supplementary Table 8

Window count data for the input samples of MBD cohort II. For each input sample of MBD cohort II, the number of mapped reads in each 5 kb genomic window (2.5 kb overlapping moving windows) is given.

sdata20164-s9.txt (243.3MB, txt)
sdata20164-isa1.zip (10.9KB, zip)

Acknowledgments

The authors thank Rosa Noguera, Johannes H. Schulte and Raymond L. Stallings for sharing primary tumor samples, and NXTGNT for the sequencing services. The work is further supported by the Emmanuel Van der Schueren Foundation (scientific partner of the Flemish League Against Cancer (VLK)), the Fournier-Majoie Foundation (FFM) and the Belgian National Lottery. A.D. was a recipient of a grant of the Research Foundation Flanders (FWO) and an Emmanuel Van der Schueren research grant (VLK).

Footnotes

The authors declare no competing financial interests.

Data Citations

  1. Decock A., Ongenaert M., Speleman F., Vandesompele J. 2015. Gene Expression Omnibus . GSE69224
  2. Decock A., Ongenaert M., Speleman F., Vandesompele J. 2015. Gene Expression Omnibus . GSE69243
  3. Decock A., Ongenaert M., Speleman F., Vandesompele J. 2015. Gene Expression Omnibus . GSE69268
  4. Decock A., Ongenaert M., Speleman F., Vandesompele J. 2015. Gene Expression Omnibus . GSE69279

References

  1. Brodeur G. M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3, 203–216 (2003). [DOI] [PubMed] [Google Scholar]
  2. Molenaar J. J. et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589–593 (2012). [DOI] [PubMed] [Google Scholar]
  3. Valentijn L. J. et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat. Genet. 47, 1411–1414 (2015). [DOI] [PubMed] [Google Scholar]
  4. Peifer M. et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 526, 700–704 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Decock A., Ongenaert M., Vandesompele J. & Speleman F. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings. Epigenetics 6, 962–970 (2011). [DOI] [PubMed] [Google Scholar]
  6. Carén H. et al. Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer 11, 66 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Decock A. et al. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers. Genome Biol. 13, R95 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Duijkers F. A. et al. Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. Cell. Oncol. 36, 351–362 (2013). [DOI] [PubMed] [Google Scholar]
  9. Mayol G. et al. DNA hypomethylation affects cancer-related biological functions and genes relevant in neuroblastoma pathogenesis. PLoS ONE 7, e48401 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Yáñez Y. et al. Two independent epigenetic biomarkers predict survival in neuroblastoma. Clin. Epigenetics 7, 1–14 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gómez S. et al. DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights. Epigenomics 7, 1137–1153 (2015). [DOI] [PubMed] [Google Scholar]
  12. Schramm A. et al. Mutational dynamics between primary and relapse neuroblastomas. Nat. Genet. 47, 872–877 (2015). [DOI] [PubMed] [Google Scholar]
  13. Stirzaker C., Taberlay P. C., Statham A. L. & Clark S. J. Mining cancer methylomes: prospects and challenges. Trends Genet. 30, 75–84 (2014). [DOI] [PubMed] [Google Scholar]
  14. Decock A. et al. Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. Oncotarget 7, 1960–1972 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Brodeur G. M. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol. 11, 1466–1477 (1993). [DOI] [PubMed] [Google Scholar]
  16. Mestdagh P. et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol. Cell 40, 762–773 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Eschenburg G., Eggert A., Schramm A., Lode H. N. & Hundsdoerfer P. Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis. Cancer Res. 72, 2645–2656 (2012). [DOI] [PubMed] [Google Scholar]
  18. Kumps C. et al. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes. PLoS ONE 8, e52321 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sante T. et al. ViVar: a comprehensive platform for the analysis and visualization of structural genomic variation. PLoS ONE 9, e113800 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Langmead B. & Salzberg S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Li H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Quinlan A. R. & Hall I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lassmann T., Hayashizaki Y. & Daub C. O. SAMStat: monitoring biases in next generation sequencing data. Bioinformatics 27, 130–131 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. De Meyer T. et al. Quality evaluation of methyl binding domain based kits for enrichment DNA-methylation sequencing. PLoS ONE 8, e59068 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mortazavi A., Williams B. A., McCue K., Schaeffer L. & Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621–628 (2008). [DOI] [PubMed] [Google Scholar]
  26. Zhang Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Thorvaldsdóttir H., Robinson J. T. & Mesirov J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178–192 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Anders S. & Huber W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Minoche A. E., Dohm J. C. & Himmelbauer H. Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and genome analyzer systems. Genome Biol. 12, R112 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Yu Y. et al. Comprehensive RNA-Seq transcriptomic profiling across 11 organs, 4 ages, and 2 sexes of Fischer 344 rats. Sci. Data 1, 140013 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Banelli B. et al. A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype. Lab. Invest. 92, 458–465 (2012). [DOI] [PubMed] [Google Scholar]
  32. Li H. & Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Feng X., Grossman R. & Stein L. PeakRanger: a cloud-enabled peak caller for ChIP-seq data. BMC Bioinformatics 12, 139 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lan X. et al. High resolution detection and analysis of CpG dinucleotides methylation using MBD-seq technology. PLoS ONE 6, e22226 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Lienhard M., Grimm C., Morkel M., Herwig R. & Chavez L. MEDIPS: Genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments. Bioinformatics 30, 284–286 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stark R. & Brown G. D. DiffBind: differential binding analysis of ChIP-seq peak data. http://bioconductor.org/packages/release/bioc/vignettes/DiffBind/inst/doc/DiffBind.pdf (2011).
  37. Robinson M. D., McCarthy D. J. & Smyth G. K. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Hong F. et al. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22, 2825–2827 (2006). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Citations

  1. Decock A., Ongenaert M., Speleman F., Vandesompele J. 2015. Gene Expression Omnibus . GSE69224
  2. Decock A., Ongenaert M., Speleman F., Vandesompele J. 2015. Gene Expression Omnibus . GSE69243
  3. Decock A., Ongenaert M., Speleman F., Vandesompele J. 2015. Gene Expression Omnibus . GSE69268
  4. Decock A., Ongenaert M., Speleman F., Vandesompele J. 2015. Gene Expression Omnibus . GSE69279

Supplementary Materials

Supplementary Table 1

Using BamUtil, basic sequencing statistics of each sample of MBD cohort I and II are computed. Given are the total read numbers, and the number and percentage of properly paired and duplicate reads of each sample of MBD cohort I (a) and II (enriched samples in (b); input samples in (c)).

sdata20164-s2.xls (31.5KB, xls)
Supplementary Table 2

Using SAMStat, the mapping quality scores of each sample of MBD cohort I and II are analyzed. Given are the numbers and percentages of mapped reads across the different mapping quality ranges, as determined by SAMStat ((a) enriched samples of MBD cohort I, (b) enriched samples of MBD cohort II and (c) input samples of MBD cohort II).

sdata20164-s3.xls (49.5KB, xls)
Supplementary Table 3

Promoter count data for the MBD-enriched samples of MBD cohort I. For each MBD-enriched sample of MBD cohort I, the number of mapped reads in each Ensembl Transcript promoter region (-1500 bp to +500 bp around TSS) is given.

sdata20164-s4.txt (22.1MB, txt)
Supplementary Table 4

Promoter count data for the MBD-enriched samples of MBD cohort II. For each MBD-enriched sample of MBD cohort II, the number of mapped reads in each Ensembl Transcript promoter region (-1500 bp to +500 bp around TSS) is given.

sdata20164-s5.txt (35.1MB, txt)
Supplementary Table 5

Promoter count data for the input samples of MBD cohort II. For each input sample of MBD cohort II, the number of mapped reads in each Ensembl Transcript promoter region (-1500 bp to +500 bp around TSS) is given.

sdata20164-s6.txt (37.5MB, txt)
Supplementary Table 6

Window count data for the MBD-enriched samples of MBD cohort I. For each MBD-enriched sample of MBD cohort I, the number of mapped reads in each 5 kb genomic window (2.5 kb overlapping moving windows) is given.

sdata20164-s7.txt (172.1MB, txt)
Supplementary Table 7

Window count data for the MBD-enriched samples of MBD cohort II. For each MBD-enriched sample of MBD cohort II, the number of mapped reads in each 5 kb genomic window (2.5 kb overlapping moving windows) is given.

sdata20164-s8.txt (239.7MB, txt)
Supplementary Table 8

Window count data for the input samples of MBD cohort II. For each input sample of MBD cohort II, the number of mapped reads in each 5 kb genomic window (2.5 kb overlapping moving windows) is given.

sdata20164-s9.txt (243.3MB, txt)
sdata20164-isa1.zip (10.9KB, zip)

Articles from Scientific Data are provided here courtesy of Nature Publishing Group

RESOURCES